Jon Faiz Kayyem, Director, on September 23, 2026, executed a purchase for 5,000 shares in Inhibrx Biosciences (INBX) for $500,000. Following the Form 4 filing with the SEC, Kayyem has control over a total of 1,074,046 common shares of the company, with 1,074,046 controlled indirectly.
SEC Filing:
Jeffrey D Benjamin, Director, on September 18, 2026, sold 39,067 shares in Gold.com (GOLD) for $1,740,305. Following the Form 4 filing with the SEC, Benjamin has control over a total of 1,121,054 common shares of the company, with 685,268 shares held directly and 435,786 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1591588/000119401626000008/xslF345X05/form4-09222026_090944.xml
Brian E O'Toole, Director, CEO, and President, on September 21, 2026, sold 20,000 shares in Blacksky Technology (BKSY) for $457,600. Following the Form 4 filing with the SEC, O'Toole has control over a total of 1,043,396 Class A common shares of the company, with 1,043,396 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1753539/000175353926000147/xslF345X05/wk-form4_1790113118.xml
Brian Savage, Interim Chief Legal Officer, on September 18, 2026, sold 7,342 shares in Teva Pharmaceutical Industries (TEVA) for $285,215. Following the Form 4 filing with the SEC, Savage has control over a total of 8,500 ordinary shares of the company, with 8,500 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/818686/000119312526398105/xslF345X05/ownership.xml